News

The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by ...
Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...
With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...
Dealmaking is in style again under President Donald Trump. Potential takeover targets include C3.ai, Viking Therapeutics, and ...
AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...
Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...
Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...
Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...
The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...
Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van ...
An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...